Natrixam (Indapamide, Amlodipine Besilate)

Indapamide and Amlodipine Besilate, the active ingredients in Natrixam, are a thiazide‑like diuretic and a calcium‑channel blocker presented as oral tablets for oral use. They are prescribed to lower elevated blood pressure in adults with hypertension and to reduce associated cardiovascular risk.

GNH USA supplies Natrixam as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support global distribution. Customers benefit from reliable lead times and comprehensive after‑sales support.

Natrixam combines a thiazide‑like diuretic and a calcium‑channel blocker to treat hypertension, a major cardiovascular disease. - Hypertension (essential): lowers systolic and diastolic blood pressure, improving overall cardiovascular risk profile. - Hypertension with fluid retention: provides diuretic action to reduce edema while controlling blood pressure. - Hypertension uncontrolled on monotherapy: adds complementary mechanisms to achieve target blood pressure when a single agent is insufficient.

Natrixam may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache: mild to moderate headache occurring shortly after dosing. - Peripheral edema: swelling of the ankles or lower legs. - Dizziness or light‑headedness: especially when standing quickly. - Flushing: transient warmth and redness of the skin. - Fatigue: general feeling of tiredness. - Nausea: mild stomach discomfort.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure leading to fainting. - Electrolyte imbalance: significant changes in potassium or sodium levels. - Angio‑edema: rapid swelling of face, lips, or airway. - Hepatic dysfunction: abnormal liver enzyme elevations. - Cardiac arrhythmias: irregular heart rhythms. - Allergic reactions: rash, itching, or anaphylaxis.

When prescribing Natrixam, clinicians should consider several safety precautions to optimize therapy and reduce risk. - Renal function: assess kidney function before initiation and monitor periodically. - Electrolytes: check serum potassium and sodium levels, especially in patients on other diuretics. - Cardiovascular status: use caution in patients with severe aortic stenosis or heart failure. - Concomitant antihypertensives: avoid excessive blood pressure lowering when combined with other agents. - Pregnancy and lactation: evaluate risk‑benefit, as safety data are limited. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Natrixam can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase amlodipine levels. - Lithium: concurrent use can raise lithium concentrations, risking toxicity. - NSAIDs (high dose): may reduce diuretic effect and impair renal function.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may lower amlodipine exposure. - Other antihypertensives (e.g., ACE inhibitors, beta‑blockers): increase risk of hypotension. - Diuretics (e.g., furosemide): additive electrolyte disturbances. - Antacids containing aluminum or magnesium: may affect indapamide absorption.